QPPV.COM KNOWLEDGE ASSESSMENT

EMA, European Commission, National Competent Authorities, CHMP, PRAC and CMDh: Who Does What?

Test your understanding of the concepts covered by EMA, European Commission, National Competent Authorities, CHMP, PRAC and CMDh: Who Does What?.

Question 1 of 10Pass mark: 80%

Question 1 of 10 A newly detected safety signal is being reviewed. Which interpretation is most appropriate?

The signal automatically proves causality and requires immediate withdrawal The signal is an initial concern that must be assessed with the totality of available evidence The signal can be assessed only by the European Commission The signal is legally equivalent to a variation decision

Question 2 of 10 Which sequence best represents the simplified architecture of a centralised marketing-authorisation application?

Applicant, national authorisation, CMDh coordination, PRAC licensing Applicant, EMA-coordinated scientific assessment, CHMP opinion, Commission legal decision Applicant, Commission scientific assessment, CHMP legal decision, national inspection Applicant, PRAC opinion, CMDh authorisation, Commission implementation in every case

Question 3 of 10 Which statement correctly describes post-authorisation supervision in the EU medicines system?

It is performed exclusively by the Commission It is performed exclusively by EMA and its committees It is a distributed network activity involving MAHs, national authorities, EMA, committees and, where applicable, the Commission It ends once the marketing authorisation has been granted

Question 4 of 10 What is the role of a rapporteur in a scientific assessment?

To independently grant or refuse the marketing authorisation To lead important parts of the assessment and prepare scientific work for consideration by the relevant committee To replace the national competent authorities in all inspections To adopt the European Commission's legal decision

Question 5 of 10 Which approach is most reliable when interpreting an EMA regulatory document?

Assume the document is legally binding because it appears on the EMA website Identify the procedure, legal basis, issuing body, type of output and subsequent legal or operational step Focus only on the document title and the product name Treat all committee outputs as equivalent to Commission decisions

Question 6 of 10 What is the best general description of EMA's role in the European medicines regulatory network?

A single EU regulator that replaces all national medicines authorities A Union agency that coordinates scientific expertise and provides regulatory infrastructure within its mandate A legislative body that creates pharmaceutical law independently of the Member States A national licensing authority acting on behalf of every Member State

Question 7 of 10 A national competent authority supplies an expert who contributes to a centralised assessment. What does this demonstrate?

The centralised procedure has become a national authorisation procedure National authorities can contribute expertise to Union procedures while retaining their national regulatory responsibilities The expert independently determines the final marketing-authorisation decision EMA has delegated all legal decision-making to that national authority

Question 8 of 10 Which institutional pairing is most accurate?

PRAC — coordination of all MRP and DCP licensing disagreements CMDh — specialist pharmacovigilance signal assessment for human medicines CHMP — scientific assessment of human medicines within its legal mandate European Commission — routine operational inspection of every regulated site

Question 9 of 10 A marketing-authorisation holder records a PRAC recommendation as the date on which the legally required product-information change took effect. What is the main conceptual error?

PRAC cannot assess product information Scientific assessment and regulatory implementation are separate events, and the legally effective step may occur later Product information can never be changed after authorisation Only rapporteurs can approve product-information changes

Question 10 of 10 Why is the statement "EMA approved the medicine" potentially imprecise for a centrally authorised product?

EMA has no role in centralised applications EMA coordinates the scientific and regulatory process, whereas the Commission adopts the legal marketing-authorisation decision Only national competent authorities can assess centrally authorised medicines CHMP, rather than EMA, is a separate legal authority that grants all Union authorisations

QPPV.com

EMA, European Commission, National Competent Authorities, CHMP, PRAC and CMDh: Who Does What?

Cookie Settings